Hypertensive emergencies, characterized by severe elevations in blood pressure (BP) exceeding 180/120 mm Hg, are critical conditions that require immediate medical intervention. These situations are associated with evidence of progressive target organ damage. This article aims to provide a comprehensive understanding of hypertensive emergencies and their management for healthcare professionals.
Understanding the pathophysiology of hypertensive emergencies is pivotal for effective management. The underlying mechanism involves the sudden increase in systemic vascular resistance, leading to endothelial injury and the release of vasoconstrictors. This results in further BP elevation, causing a vicious cycle of uncontrolled hypertension.
Patients with hypertensive emergencies often present with symptoms related to the affected organ system. These may include severe headache, visual disturbances, chest pain, dyspnea, or neurological deficits.
Diagnosis involves a thorough history, physical examination, and appropriate laboratory investigations. The aim is to identify end-organ damage, which may include hypertensive encephalopathy, acute coronary syndrome, acute renal failure, or aortic dissection.
Management of hypertensive emergencies requires a careful and rapid reduction of BP. The goal is to decrease the mean arterial pressure by no more than 25% within the first hour, then to 160/100-110 mm Hg over the next 2-6 hours. Rapid reduction beyond this can lead to ischemic complications. Intravenous antihypertensive agents are preferred, with the choice of drug tailored to the clinical scenario.
Hypertensive emergencies are potentially life-threatening situations that require prompt recognition and management. Understanding the pathophysiology, clinical manifestations, diagnostic approach, and management strategies can help healthcare professionals provide optimal care for these patients. Continuous education and research are needed to further improve patient outcomes in hypertensive emergencies.
1.
Imetelstat for MDS-relateret anemia er godkendt af Food and Drug Administrations panel.
2.
Navigating breast cancer diagnosis, treatment, and survivorship in Ethiopia
3.
No Gestational Diabetes-Cancer Link; Cholesterol and Cancer; Oncologist Saves Umpire
4.
Specialized imaging improves overall prostate cancer survival by identifying benefits of salvage radiotherapy
5.
Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma
1.
Ferroptosis as a Therapeutic Target in Cancer
2.
Subchorionic Hematoma: Causes, Symptoms, and Treatment
3.
Adaptive Cell Therapies for Solid Tumors
4.
Engineered Niches for Blood-Cell Regeneration: Current Concepts and Clinical Implications
5.
Unlocking the Potential of Hemin: A Novel Approach to Health and Wellbeing
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
2.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
5.
Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation